By the Numbers: Top 10 Pharma & Biopharma Companies

A preview to Contract Pharma’s Guide to the Top 20 Pharma and Biopharma Companies, the following is a list of the top 10 Pharma and Biopharma companies by Pharmaceutical sales in U.S. Millions for FY2025. (excludes consumer healthcare, medical device, diagnostics division sales)

Contract Pharma’s annual guide to the 20 biggest Pharma and Biopharma players highlights key financials, top selling drugs, acquisitions and alliances, drug approvals, pipeline advances, executive moves, and more. Coming soon, Contract Pharma’s July/August Top 20 Companies Report!

1. Lilly: $65,179
2. Merck: $65,011
3. Roche: $62,598
4. Pfizer: $62,579
5. Abbvie: $61,160
6. Johnson & Johnson: $60,401
7. AstraZeneca: $58,739
8. Novartis: $54,532
9. Sanofi: $51,318
10. Novo Nordisk: $48,680

Lilly
FY Revenues: $65,179 (+45%)
Net Income: $20,640 (+95%)
R&D Expenses: $13,337 (+21%)

Merck
FY Revenues: $65,011 (+1%)
Net Income: $18,263 (+7%)
R&D Expenses: $15,789 (-12%)

Roche
FY Revenues: $77,871 (+2%)
Pharma Revenues: $62,598 (+3%)
Net Income: $17,468 (+50%)
R&D Expenses: $14,304 (-15%)

Pfizer
FY Revenues: $62,579 (-2%)
Net Income: $7,771 (-3%)
R&D Expenses: $10,437 (-4%)

Abbvie
FY Revenues: $61,160 (+9%)
Net Income: $ 4,226 (-1%)
R&D Expenses: $9,096 (-29%)

Johnson & Johnson
FY Revenues: $94,193 (+6%)
Pharma Sales $60,401 (+6%)
Net Income: $26,804 (+90%)
R&D Expenses: $14,665 (-15%)

AstraZeneca
FY Revenues: $ 58,739 (+9%)
Net Income: $10,233 (+45)
R&D Expenses:14,232 (+5%)

Novartis
FY Revenues: $54,532 (+8%)
Net Income: $13,967 (+17%)
R&D Expenses:11,200 (-12%)

Sanofi
FY Revenues: $51,318 (+6%)
Net Income: $9,191 (+41%)
R&D Expenses: $9,225 (+6%)

Novo Nordisk
FY Revenues: $48,680 (+6%)
Net Income: $16,134 (+1%)
R&D Expenses: $8,197 (+8%)

See last year’s rankings based on 2024 Pharma/Biopharma Sales